We could not find any results for:
Make sure your spelling is correct or try broadening your search.
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform.
TCBP Adjourns General Meeting Until a Later Date PR Newswire EDINBURGH, Scotland, March 19, 2024 EDINBURGH, Scotland, March 19, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or...
TCBP Announces Exercise of Series D Warrants For Cash PR Newswire EDINBURGH, Scotland, March 18, 2024 โขย Company receives gross proceeds of $1.26 M from transaction EDINBURGH, Scotland, March 18...
false 0001872812 0001872812 2024-02-29 2024-02-29 0001872812 TCBP:AmericanDepositarySharesEachRepresentingMember 2024-02-29 2024-02-29...
Bryan Kobel, CEO of TCBP, Appears on Nationally Syndicated "The Big Biz Show" PR Newswire EDINBURGH, Scotland, March 1, 2024 EDINBURGH, Scotland, March 1, 2024 /PRNewswire/ -- TC...
/C O R R E C T I O N -- TC BioPharm/ PR Newswire EDINBURGH, Scotland, Feb. 27, 2024 In the news release, TCBP Announces Shareholder Update Call on March 5th 2024, issued 27-Feb-2024 by TC...
TCBP Announces Shareholder Update Call on March 5th 2024 PR Newswire EDINBURGH, Scotland, Feb. 27, 2024 EDINBURGH, Scotland, Feb. 27, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC...
TCBP Announces MHRA Acceptance of Amendment for ACHIEVE UK Trial PR Newswire EDINBURGH, Scotland, Feb. 22, 2024 Increases dose level in line with Cohort 2 in INDChanges from "in patient" to "out...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions